209 related articles for article (PubMed ID: 35579198)
21. Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.
Cobain EF; Wu YM; Vats P; Chugh R; Worden F; Smith DC; Schuetze SM; Zalupski MM; Sahai V; Alva A; Schott AF; Caram MEV; Hayes DF; Stoffel EM; Jacobs MF; Kumar-Sinha C; Cao X; Wang R; Lucas D; Ning Y; Rabban E; Bell J; Camelo-Piragua S; Udager AM; Cieslik M; Lonigro RJ; Kunju LP; Robinson DR; Talpaz M; Chinnaiyan AM
JAMA Oncol; 2021 Apr; 7(4):525-533. PubMed ID: 33630025
[TBL] [Abstract][Full Text] [Related]
22. Impact of next generation sequencing results on clinical management in patients with hematological disorders.
Patel BJ; Barot SV; Xie Y; Cook JR; Carraway HE; Hsi ED
Leuk Lymphoma; 2021 Jul; 62(7):1702-1710. PubMed ID: 33533694
[TBL] [Abstract][Full Text] [Related]
23. [NGS-based multi-gene panel testing in hematological malignancies: therapeutic significance].
Maeda T
Rinsho Ketsueki; 2022; 63(4):302-307. PubMed ID: 35491220
[TBL] [Abstract][Full Text] [Related]
24. LYmphoid NeXt-Generation Sequencing (LYNX) Panel: A Comprehensive Capture-Based Sequencing Tool for the Analysis of Prognostic and Predictive Markers in Lymphoid Malignancies.
Navrkalova V; Plevova K; Hynst J; Pal K; Mareckova A; Reigl T; Jelinkova H; Vrzalova Z; Stranska K; Pavlova S; Panovska A; Janikova A; Doubek M; Kotaskova J; Pospisilova S
J Mol Diagn; 2021 Aug; 23(8):959-974. PubMed ID: 34082072
[TBL] [Abstract][Full Text] [Related]
25. Molecular Profiling of Hard-to-Treat Childhood and Adolescent Cancers.
Khater F; Vairy S; Langlois S; Dumoucel S; Sontag T; St-Onge P; Bittencourt H; Dal Soglio D; Champagne J; Duval M; Leclerc JM; Laverdiere C; Tran TH; Patey N; Ellezam B; Perreault S; Piché N; Samson Y; Teira P; Jabado N; Michon B; Brossard J; Marzouki M; Cellot S; Sinnett D
JAMA Netw Open; 2019 Apr; 2(4):e192906. PubMed ID: 31026031
[TBL] [Abstract][Full Text] [Related]
26. Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients.
Lee SH; Lee B; Shim JH; Lee KW; Yun JW; Kim SY; Kim TY; Kim YH; Ko YH; Chung HC; Yu CS; Lee J; Rha SY; Kim TW; Jung KH; Im SA; Moon HG; Cho S; Kang JH; Kim J; Kim SK; Ryu HS; Ha SY; Kim JI; Chung YJ; Kim C; Kim HL; Park WY; Noh DY; Park K
Cancer Res Treat; 2019 Jan; 51(1):211-222. PubMed ID: 29690749
[TBL] [Abstract][Full Text] [Related]
27. Concurrent detection of targeted copy number variants and mutations using a myeloid malignancy next generation sequencing panel allows comprehensive genetic analysis using a single testing strategy.
Shen W; Szankasi P; Sederberg M; Schumacher J; Frizzell KA; Gee EP; Patel JL; South ST; Xu X; Kelley TW
Br J Haematol; 2016 Apr; 173(1):49-58. PubMed ID: 26728869
[TBL] [Abstract][Full Text] [Related]
28. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
[TBL] [Abstract][Full Text] [Related]
29. Application of Comprehensive Genomic Profiling-Based Next-Generation Sequencing Assay to Improve Cancer Care in a Developing Country.
Cifuentes C; Lombana M; Vargas H; Laguado P; Ruiz-Patiño A; Rojas L; Navarro U; Vargas C; Ricaurte L; Arrieta O; Zatarain-Barron L; Zapata L; González G; Ortiz C; Bernal L; Restrepo JG; Viola L; Grosso F; Zapata R; Mantilla W; Carranza H; Bustillo I; Llinas N; Duarte R; Rodríguez J; Archila P; Ávila J; Bermúdez M; Gámez T; Sotelo C; Otero J; Forero E; Lema M; Limpias C; Ordóñez-Reyes C; Mejía S; Rolfo C; Rosell R; Cardona AF; ;
Cancer Control; 2023; 30():10732748231175256. PubMed ID: 37148308
[TBL] [Abstract][Full Text] [Related]
30. Detection of genome-wide copy number variants in myeloid malignancies using next-generation sequencing.
Shen W; Paxton CN; Szankasi P; Longhurst M; Schumacher JA; Frizzell KA; Sorrells SM; Clayton AL; Jattani RP; Patel JL; Toydemir R; Kelley TW; Xu X
J Clin Pathol; 2018 Apr; 71(4):372-378. PubMed ID: 29197855
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials.
Galanina N; Bejar R; Choi M; Goodman A; Wieduwilt M; Mulroney C; Kim L; Yeerna H; Tamayo P; Vergilio JA; Mughal TI; Miller V; Jamieson C; Kurzrock R
Cancers (Basel); 2018 Dec; 11(1):. PubMed ID: 30583461
[No Abstract] [Full Text] [Related]
32. Genomics-Enabled Precision Medicine for Cancer.
Roos A; Byron SA
Cancer Treat Res; 2019; 178():137-169. PubMed ID: 31209844
[TBL] [Abstract][Full Text] [Related]
33. Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing.
Cai H; Jing C; Chang X; Ding D; Han T; Yang J; Lu Z; Hu X; Liu Z; Wang J; Shang L; Wu S; Meng P; Lin L; Zhao J; Nie M; Yin K
J Transl Med; 2019 Jun; 17(1):189. PubMed ID: 31164161
[TBL] [Abstract][Full Text] [Related]
34. Genomic profiling of esophageal squamous cell carcinoma (ESCC)-Basis for precision medicine.
Yang JW; Choi YL
Pathol Res Pract; 2017 Jul; 213(7):836-841. PubMed ID: 28554745
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive genomic profiling for oncological advancements by precision medicine.
Pankiw M; Brezden-Masley C; Charames GS
Med Oncol; 2023 Nov; 41(1):1. PubMed ID: 37993657
[TBL] [Abstract][Full Text] [Related]
36. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences.
Wang K; Johnson A; Ali SM; Klempner SJ; Bekaii-Saab T; Vacirca JL; Khaira D; Yelensky R; Chmielecki J; Elvin JA; Lipson D; Miller VA; Stephens PJ; Ross JS
Oncologist; 2015 Oct; 20(10):1132-9. PubMed ID: 26336083
[TBL] [Abstract][Full Text] [Related]
38. Genomic profiling of multiple myeloma: New insights and modern technologies.
Hultcrantz M; Yellapantula V; Rustad EH
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101153. PubMed ID: 32139018
[TBL] [Abstract][Full Text] [Related]
39. Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
van Geelen CT; Savas P; Teo ZL; Luen SJ; Weng CF; Ko YA; Kuykhoven KS; Caramia F; Salgado R; Francis PA; Dawson SJ; Fox SB; Fellowes A; Loi S
Breast Cancer Res; 2020 Aug; 22(1):91. PubMed ID: 32811538
[TBL] [Abstract][Full Text] [Related]
40. Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study.
Smyth LM; Reichel JB; Tang J; Patel JAA; Meng F; Selcuklu DS; Houck-Loomis B; You D; Samoila A; Schiavon G; Li BT; Razavi P; Piscuoglio S; Reis-Filho JS; Taylor BS; Baselga J; Solit DB; Hyman DM; Berger MF; Chandarlapaty S
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
